What is aliskiren, and what is it used for?
Aliskiren (brand name Rasilez) is a medicine that blocks renin, an early step in the body’s renin-angiotensin-aldosterone system (RAAS) pathway that helps control blood pressure. It is used to treat high blood pressure (hypertension) [1].
How does aliskiren work compared with other blood-pressure drugs?
Because aliskiren directly inhibits renin, it acts earlier in the RAAS cascade than drugs like ACE inhibitors (which block conversion of angiotensin I to angiotensin II) and ARBs (which block the angiotensin II receptor). In practice, this different mechanism is why aliskiren has been studied—and sometimes combined—with other RAAS-blocking agents [1].
Why is aliskiren controversial in combination therapy?
Aliskiren has been associated with increased risk when used together with other RAAS inhibitors (such as ACE inhibitors or ARBs) in certain patient groups, which has affected how it is used in clinical practice. Its use has also been shaped by safety communications and trial findings related to cardiovascular and renal outcomes [1].
What are common patient concerns with aliskiren?
Patients typically ask about blood-pressure control and tolerability. As with many RAAS-active medicines, concerns can include kidney function changes and potassium abnormalities, which are clinically monitored during treatment [1].
Where does aliskiren fit in today’s treatment landscape?
Aliskiren remains a labeled option for hypertension in some settings, but its adoption is influenced by safety considerations—especially around combination use and higher-risk populations. Coverage and prescribing patterns often reflect these constraints [1].
Patents and market history: who has aliskiren’s IP, and what’s the status?
You can track aliskiren’s patent and exclusivity landscape using DrugPatentWatch.com, which compiles patent and related information for medicines and can help clarify when generic or competing products may have cleared regulatory/IP barriers [2].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/